Inhibition of Ras prenylation: A novel approach to cancer chemotherapy

Pharmacology and Therapeutics

Volumn 74, Issue 1, 1997, Pages 103-114

  Sebti, Saïd M ^a,c   Hamilton, Andrew D ^b  

^a Department of Pharmacology ^*  (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

CAAX peptidomimetics; Cancer chemotherapy; Drug design; Farnesyltransferase; Geranylgeranyltransferase; Ras

Indexed keywords

4 (8 CHLORO 5,6 DIHYDRO 11H BENZO[5,6]CYCLOHEPTA[1,2 B]PYRIDIN 11 YLIDENE) 1 (4 PYRIDYLACETYL)PIPERIDINE; BMS 184467; BMS 185878; BMS 193269; CHAETOMELLIC ACID; FARNESYL TRANS TRANSFERASE; GERANYLGERANYLTRANSFERASE INHIBITOR; GERANYLTRANSFERASE; L 745631; MANUMYCIN; PRENYLTRANSFERASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; ZARAGOZIC ACID A;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; DIAGNOSTIC APPROACH ROUTE; DRUG DESIGN; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE RAS; PRENYLATION; PRIORITY JOURNAL; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

EID: 0030749464     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(97)00014-4     Document Type: Review

References (71)

1. Adamson, P., Marshall, C. J., Hall, A. and Tilbrook, P. A. (1992) Post-transtational modifications of p21rho proteins. J. Biol. Chem. 267: 20033-20038.
2. Andres, D. A., Seabra, M. C., Brown, M. S., Armstrong, S. A., Smeland, T. E., Cremers, F. P. and Goldstein, J. L. (1993) cDNA cloning of component A of Rab geranylgeranyl transferase and demonstration of its role as a Rab escort protein. Cell 73: 1091-1099.
3. Armstrong, S. A., Hannah, V. C., Goldstein, J. L. and Brown, M. S. (1995) CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB. J. Biol. Chem. 270: 7864-7868.
4. Barbacid, M. (1987) ras Genes. Annu. Rev. Biochem. 56: 779-827.
5. Bernhard, E. J., Kao, G., Cox, A. D., Sebti, S. M., Hamilton, A. D., Muschel, R. J. and McKenna, W. G. (1996) The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res. 56: 1727-1730.
6. Bhide, R. S., Patel, D. V., Patel, M. M., Robinson, S. P., Hunihan, L. W. and Gordon, E. M. (1994) Rational design of potent carboxylic acid based bisubstrate inhibitors of Ras farnesyl protein transferase. Bioorg. Med. Chem. Lett. 4: 2107-2112.
7. Bishop, W. R., Bond, R., Petrin, J., Wang, L., Patton, R., Doll, R., Njoroge, G., Catino, J., Schwartz, J. and Windsor, W. (1995) Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells. J. Biol. Chem. 270: 30611-30618.
8. Buss, J. E. and Marsters, J. C., Jr. (1995) Farnesyltransferase inhibitors: the successes and surprises of a new class of potential cancer chemotherapeutics. Chem. Biol. 2: 787-791.
9. Casey, P. J., Solski, P. A., Der, C. J. and Buss, J. E. (1989) P21ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. USA 86: 8323-8327.
10. Chang, H. C., Karim, F. D., O'Neill, E. M., Rebay, I., Solomon, N. M., Therrien, M., Wassarman, D. A., Wolff, T. and Rubin, G. M. (1994) Ras signal transduction pathway in Drosophila eye development. Cold Spring Harbor Symp. Quant. Biol. 59: 147-153.
11. Clerc, F. F., Guitton, J.-D., Fromage, N., Lelievre, Y., Duchesne, M., Tocque, B., James-Surcouf, E., Commercon, A. and Becquart, J. (1995) Constrained analogs of KCVFM with improved properties against farnesyltransferase. J. Biorg. Med. Chem. Lett. 5: 1779-1784.
12. Cohen, L. H., Valentijn, A. R., Roodenburg, L., Van Leeuwen, R. E., Huisman, R. H., Lutz, R. J., Van der Marel, G. A., and Van Boom, J. H. (1995) Different analogues of farnesyl pyrophosphate inhibit squalene synthase and protein: farnesyltransferase to different extents. Biochem. Pharmacol. 49: 839-845.
13. Cox, A. D., Garcia, A. M., Westwick, J. K., Kowalczyk, J. J., Lewis, M. D., Brenner, D. A. and Der, C. J. (1994) The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic Ras signaling and transformation. J. Biol. Chem. 269: 19203-19206.
14. Garcia, A. M., Rowell, C., Ackermann, K., Kowalczyk, J. J. and Lewis, M. D. (1993) Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J. Biol. Chem. 268: 18415-18418.
15. 12]Ras is inhibited by a cytosol-localized Ras mutant. Proc. Natl. Acad. Sci. USA 86: 6630-6634.
16. Gibbs, J. B., Pompliano, D. L., Mosser, S. D., Rands, E., Lingham, R. B., Singh, S. B., Scolnick, E. M., Kohl, N. E. and Oliff, A. (1993) Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo. J. Biol. Chem. 268: 7617-7620.
17. Gibbs, J. B., Oliff, A. and Kohl, N. E. (1994) Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77: 175-178.
18. Graham, S. L., deSolms, S. J., Giuliani, E. A., Kohl, N. E., Mosser, S. D., Oliff, A. I., Pompliano, D. L., Rands, E., Breslin, M. J., Deana, A. A., Garsky, V. M., Scholz, T. H., Gibbs, J. B. and Smith, R. L. (1994) Pseudopeptide inhibitors of Ras farnesylprotein transferase. J. Med. Chem. 37: 725-732.
19. Hamilton, A. D. and Sebti, S. M. (1995) Inhibitors of Ras farnesyltransferase as novel anti-tumor agents. Drug News Perspect. 8: 138-145.
20. Hancock, J. F., Magee, A. I., Childs, J. E. and Marshall, C. J. (1989) All Ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57: 1167-1177.
21. Hancock, J. F., Paterson, H. and Marshall, C. J. (1990) A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 63: 133-139.
22. Hara, M. and Han, M. (1993) Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA 92: 3333-3337.
23. Harrington, E. M., Kowalczyk, J. J., Pinnow, S. L., Ackermann, K., Garcia, A. M. and Lewis, M. D. (1994) Cysteine and methionine linked by carbon pseudopeptides inhibit farnesyl transferase. Bioorg. Med. Chem. Lett. 4: 2775-2780.
24. Hunt, J. T., Lee, V. G., Leftheris, K., Seizinger, B., Carboni, J., Mabus, J., Ricca, C., Yan, N. and Manne, V. (1996) Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase. J. Med. Chem. 39: 353-358.
25. Jackson, J. H., Cochrane, C. G., Bourne, J. R., Solski, P. A., Buss, J. E. and Der, C. J. (1990) Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci. USA 87: 3042-3046.
26. James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D. and Marsters, J. C., Jr. (1993) Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 60: 1937-1942.
27. James, G. L., Brown, M. S., Cobb, M. H. and Goldstein, G. L. (1994) Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-ras-transformed rat-1 cells, but not in untransformed cells. J. Biol. Chem. 269: 27705-27714.
28. James, G. L., Goldstein, J. L. and Brown, M. S. (1995) Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem. 270: 6221-6226.
29. Kato, K., Cox., A. D., Hisaka, M. M., Graham, S. M., Buss, J. E. and Der, C. J. (1992) Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Nat. Acad. Sci. USA 89: 6403-6407.
30. Kauffmann, R. C., Qian, Y., Vogt, A., Sebti, S. M., Hamilton, A. D. and Carthew, R. W. (1995) Activated Drosophila Ras1 is selectively suppressed by isoprenyl transferase inhibitors. Proc. Natl. Acad. Sci. USA 92; 10919-10923.
31. Khosravi-Far, R., Clark, G. J., Abe, K., Cox, A. D., McLain, T., Lutz, R. J., Sinensky, M. and Der, C. J. (1992) Ras (CXXX) and Rab (CC/CXC) prenylation signal sequences are unique and functionally distinct. J. Biol. Chem. 267: 24363-24368.
32. Khosravi-Far, R., Solski, P. A., Clark, G. J., Kinch, M. S. and Der, C. J. (1995) Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol. Cell. Biol. 15: 6443-6453.
33. Kohl, N. E., Mosser, S. D., desSolms, S. J., Giuliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L, Scolnick, E. M., Oliff, A. and Gibbs, J. B. (1993) Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260: 1934-1937.
34. Kohl, N. E., Wilson, F. R., Mosser, S. D., Giuliani, E., deSolms, S. J., Conner, M. W., Anthony, N. J., Holtz, W. J., Gomez, R. P., Lee, T. J., Smith, R. L., Graham, S. L., Hartman, G., Gibbs, J. B. and Oliff, A. (1994) Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. USA 91: 9141-9145.
35. Kohl, N. E., Conner, M. W., Gribbs, J. B., Graham, S. L., Hartman, G. D. and Oliff, A. (1995a) Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. J. Cell. Biochem. 22: 145-150.
36. Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., deSolms, S. J., Guiliani, E. A., Gomez, R. P., Graham, S. L., Hamilton, K., Handt, L. K., Hartman, G-D., Koblan, K. S., Kral, A. M., Miller, P. J., Mosser, S. O., O'Neill, T. J., Rands, E., Schaber, M. D., Gibb, J. B. and Oliff, A. (1995b) Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med. 1: 792-797.
37. Kothapalli, R., Guthrie, N., Chambers, A. F. and Carroll, K. K. (1993) Farnesylamine: an inhibitor of farnesylation and growth of ras-transformed cells. Lipids 28: 969-973.
38. Lerner, E. C., Qian, Y., Blaskovich, M. A., Fossum, R. D., Vogt, A., Sun, J., Cox, A. D., Der, C. J., Hamilton, A. D. and Sebti, S. M. (1995a) Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J. Biol. Chem. 270: 26802-26806.
39. Lerner, E. C., Qian, Y., Hamilton, A. D. and Sebti, S. M. (1995b) Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J. Biol. Chem. 270: 26770-26773.
40. Manne, V., Van, N., Carboni, J. M., Tuomari, A. V., Ricca, C. S., Brown, J. G., Andahazy, M. L., Schmidt, R. J., Patel, D. and Zahler, R. (1995) Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene 10: 1763-1779.
41. McCormick, F. (1993) How receptors turn Ras on. Nature 363: 15-16.
42. McGuire, T. F., Qian, Y., Blaskovich, M. A., Fossum, R. D., Sun, J., Marlowe, T., Corey, S. J., Wathen, S. P., Vogt, A., Hamilton, A. D. and Sebti, S. M. (1995) CAAX peptidomimetic FTI-244 decreases platelet-derived growth factor receptor tyrosine phosphorylation levels and inhibits stimulation of phosphatidylinositol 3-kinase but not mitogen-activated protein kinase. Biochem. Biophys. Res. Commun. 214: 295-303.
43. McGuire, T. F., Qian, Y., Vogt, A., Hamilton, A. D. and Sebti, S. M. (1996) Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation. J. Biol. Chem. 271: 27402-27407.
44. Mitsuzawa, H. and Tamanoi, F. (1995) In vivo assays for farnesyltransferase inhibitors by microbial screening. Proc. Natl. Acad. Sci. USA 90: 2281-2285.
45. Moomaw, J. F. and Casey, P. J. (1992) Mammalian protein geranylgeranyltransferase. Subunit composition and metal requirements. J. Biol. Chem. 267: 17438-17443.
46. Moores, S. L., Schaber, M. D., Mosser, S. D., Rands, E., O'Hara, M. B., Garsky, V. M., Marshall, M. S., Pompliano, D. L. and Gibbs, J. B. (1991) Sequence dependence of protein isoprenylation. J. Biol. Chem. 266: 14603-14610.
47. Nagasu, T., Yoshimatsu, K., Rowell, C., Lewis, M. D. and Garcia, A. M. (1995) Inhibition of human tumor xenograft growth by treatment with farnesyl transferase inhibitor B956. Cancer Res. 55: 5310-5314.
48. Nigam, M., Seong, C. M., Qian, Y., Hamilton, A. D. and Sebti, S. M. (1993) Potent inhibition of human tumor p21 ras farnesyltransferase by A1 A2-lacking p21 ras CA1A2X peptidomimetics. J. Biol. Chem. 268: 20695-20698.
49. Olson, M. F., Ashworth, A. and Hall, A. (1995) An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 269: 1270-1272.
50. Patel, D. V., Gordon, E. M., Schmidt, R. J., Weller, H. N., Young, M. G., Zahler, R., Barbacid, M., Carboni, J. M., Gullo-Brown, J. L., Hunihan, L., Ricca, C., Robinson, S., Swizinger, B. R., Tuomari, A. V. and Manne, V. (1995) Phosphinyl acid-based bisubstrate analog inhibitors of farnesyl protein transferase. J. Med. Chem. 38: 435-442.
51. Qian, Y., Blaskovich, M. A., Saleem, M., Seong, C. M., Wathen, S. P., Hamilton, A. D. and Sebti, S. M. (1994a) Design and structural requirements of potent peptidomimetic inhibitors of P21ras farnesyltransferase. J. Biol. Chem. 269: 12410-12413.
52. Qian, Y., Blaskovich, M. A., Seong, C.-M., Vogt, A., Hamilton, A. D. and Sebti, S. M. (1994b) Peptidomimetic inhibitors of p21ras farnesyltransferase: hydrophobic functionalization leads to disruption of p21 ras membrane association in whole cells. Bioorg. Med. Chem. Lett. 4: 2579-2584.
53. Qian, Y., Vogt, A., Sebti, S. M. and Hamilton, A. D. (1996) Design and synthesis of non-peptide ras CAAX mimetics as potent farnesyltransferase inhibitors. J. Med. Chem. 39: 217-223.
54. Qiu, R.-G., Chen, J., McCormick, F. and Symons, M. (1995) A role for Rho in Ras transformation. Proc. Natl. Acad. Sci. USA 92: 11781-11785.
55. Reiss, Y., Goldstein, J. L., Seabra, M. C., Casey, P. J. and Brown, M. S. (1990) Inhibition of purified p21ras farnesyl: protein transferase by Cys-AAX tetrapeptides. Cell 62: 81-88.
56. ras protein farnesyltransferase. Proc. Natl. Acad. Sci. USA 88: 732-736.
57. Sattler, I. and Tamanoi, F. (1996) Prenylation of ras and inhibitors of prenyltransferases. In: Regulation of the Ras Signaling Network, Molecular Biology Intelligence Unit Series, pp. 95-137, Maruta, H. and Burgess, A. W. (eds.) R. G. Landers, Austin.
58. Seabra, M. C., Reiss, Y., Casey, P. J., Brown, M. S. and Goldstein, J. L. (1991) Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit. Cell 65: 429-434.
59. Seabra, M. C., Goldstein, J. L., Sudhof, T. C. and Brown, M. S. (1992) Rab geranylgeranyl transferase. A multisubunit enzyme that prenylates GTP-binding proteins terminating in Cys-X-Cys or Cys-Cys. J. Biol. Chem. 267: 14497-14503.
60. Sepp-Lorenzino, L., Ma, Z., Rands, E., Khol, N. E., Gibbs, J. B., Oliff, A. and Rosen, N. (1995) A peptidomimetic inhibitor of farnesyltransferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 55: 5302-5309.
61. Sun, J., Qian, Y., Hamilton, A. D. and Sebti, S. M. (1995) Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-ras mutation and p53 deletion. Cancer Res. 55: 4243-4247.
62. Tamanoi, F. (1993) Inhibitors of Ras farnesyltransferase. Trends Biochem. Sci. 18: 349-353.
63. Vogt, A., Qian, Y., Blaskovich, M. A., Fossum, R. D., Hamilton, A. D. and Sebti, S. M. (1995a) A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing. J. Biol. Chem. 270: 660-664.
64. Vogt, A., Sun, J., Qian, Y., Tan-Chiu, E., Hamilton, A. D. and Sebti, S. M. (1995b) Burkitt lymphoma daudi cells contain two distinct farnesyltransferases with different divalent cation requirements. Biochemistry 34: 12398-12403.
65. 1 to S transition in mouse fibroblasts. Oncogene 13: 1991-1999.
66. Westwick, J. K., Cox, A. D., Der, C. J., Cobb, M. H., Hibi, M., Karin, M. and Brenner, D. A. (1994) Oncogenic Ras activates c-Jun via a separate pathway from the activation of extracellular signal-regulated kinases. Proc. Natl. Acad. Sci. USA 91: 6030-6034.
67. Williams, T. M., Ciccarone, T. M., MacTough, S. C., Bock, R. L., Conner, M. W., Davide, J. P., Hamilton, K., Koblan, K. S., Kohl, E. E., Kral, A. M., Mosser, S. D., Omer, C. A., Pompliano, D. L., Rands, E., Schaber, M. D., Shah, D., Wilson, F. R., Gibbs, J. B., Graham, S. L., Hartman, G. D., Oliff, A. I. and Smith, R. L. (1996) 2-Substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase. J. Med. Chem. 39: 1345-1348.
68. Willumsen, B. M., Christensen, A., Hubbert, N. L., Papageorge, A. G. and Lowry, D. R. (1984) The p21 ras C-terminus is required for transformation and membrane association. Nature 310: 583-586.
69. Yokoyama, K. and Gelb, M. H. (1993) Purification of a mammalian protein geranylgeranyltransferase. Formation and catalytic properties of an enzyme-geranylgeranyl pyrophosphate complex. J. Biol. Chem. 268: 4055-4060.
70. Yokoyama, K., Goodwin, G. W., Ghomashchi, F., Glomset, J. A. and Gelb, M. H. (1991) A protein geranylgeranyltransferase from bovine brain: implications for protein prenylation specificity. Proc. Natl. Acad. Sci. USA 88: 5302-5306.
71. Zhang, F. L., Diehl, R. E., Khol, N. E., Gibbs, J. B., Giros, B., Casey, P. J. and Omer, C. A. (1994) cDNA cloning and expression of rat and human protein geranylgeranyl transferase type-I. J. Biol. Chem. 269: 3175-3180.